| Summary: | 碩士 === 國立陽明大學 === 醫務管理研究所 === 99 === Purpose: The purpose of this study is to analyze the diffusion of new drugs, and to investigate the same or different therapeutic areas of diffusion of new drugs, and to find the difference between the diffusion of brand drugs generic drugs.
Methods: This study used IMS database to observe diffusion of new drugs of diabetes, hypertension and dyslipidemia from 2005/10 to 2010/09 and compare drug trends with the product life cycle (PLC) graph. We use one-way ANOVA to analyze the differences in diffusion of new drugs. And we use logarithmic multiple regression to investigate whether classification of pharmaceutical ingredients, drug classification and dosage forms effect on drug sales amount and sales quantity or not.
Results: The results show whether the same or different therapeutic areas of new drugs, diffusion are significantly different. To concern brand drugs and generic drugs, they are treated in the same therapeutic areas or different therapeutic areas of new drugs also have significant differences; to compare drug trends of diabetes, hypertension and dyslipidemia with the product life cycle (PLC) graph, its tendency of diffusion is still very different. By the logarithmic multiple regression, we can find pharmaceutical ingredients, drug classification and dosage forms for drug sales amount and sales quantity are influential.
Conclusion: Whether the amount of sales or sales quantity, different disease or different drug classification will make different of the diffusion of new drugs. Even in the same therapeutic areas of drugs, the diffusion of new drugs are also different because of its different pharmaceutical ingredients and drug classification. To compare drug classification, brand drugs are the most popular then BA / BE generics follow by general generics. Beside the new ingredient drugs have developed a lot, and our new drugs still mainly use the traditional ingredient. Since the diffusion of the new ingredients of drugs presents a rapid growth in very short time, it can be seen the new drug is bound to become a component of future market trends. The results suggest that health authorities should support and encourage pharmaceutical companies to develop new ingredients or new therapeutic drugs, avoid spending unnecessary time and cost of drug development.
|
|---|
